Mortality risk with preadmission metformin use in patients with COVID-19 and diabetes: A meta-analysis
et al., Journal of Medical Virology, doi:10.1002/jmv.26498, Sep 2020
Metformin for COVID-19
3rd treatment shown to reduce risk in
July 2020, now with p < 0.00000000001 from 107 studies.
Lower risk for mortality, ventilation, ICU, hospitalization, progression, recovery, and viral clearance.
No treatment is 100% effective. Protocols
combine treatments.
6,200+ studies for
200+ treatments. c19early.org
|
Meta analysis of 5 studies showing lower mortality with metformin use.
23 meta analyses show significant improvements with metformin for mortality1-22,
hospitalization7,13,
progression1, and
severity8,9,13 .
Currently there are 107 metformin for COVID-19 studies, showing 37% lower mortality [33‑41%], 31% lower ventilation [15‑45%], 17% lower ICU admission [6‑26%], 17% lower hospitalization [11‑23%], and 5% fewer cases [-4‑13%].
1.
Yang et al., The effect of metformin on mortality and severity in COVID-19 patients with diabetes mellitus, Diabetes Research and Clinical Practice, doi:10.1016/j.diabres.2021.108977.
2.
Lukito et al., The Effect of Metformin Consumption on Mortality in Hospitalized COVID-19 patients: a systematic review and meta-analysis, Diabetes & Metabolic Syndrome: Clinical Research & Reviews, doi:10.1016/j.dsx.2020.11.006.
3.
Kow et al., Mortality risk with preadmission metformin use in patients with COVID-19 and diabetes: A meta-analysis, Journal of Medical Virology, doi:10.1002/jmv.26498.
4.
Hariyanto et al., Metformin use is associated with reduced mortality rate from coronavirus disease 2019 (COVID-19) infection, Obesity Medicine, doi:10.1016/j.obmed.2020.100290.
5.
Ma et al., Is metformin use associated with low mortality in patients with type 2 diabetes mellitus hospitalized for COVID-19? a multivariable and propensity score-adjusted meta-analysis, PLOS ONE, doi:10.1371/journal.pone.0282210.
6.
Parveen et al., Association of Metformin with Mortality in COVID-19 Patients: A Systematic Review and Meta-Analysis, Annals of the National Academy of Medical Sciences (India), doi:10.1055/s-0042-1760353.
7.
Li et al., Metformin in Patients With COVID-19: A Systematic Review and Meta-Analysis, Frontiers in Medicine, doi:10.3389/fmed.2021.704666.
8.
Schlesinger et al., Risk phenotypes of diabetes and association with COVID-19 severity and death: an update of a living systematic review and meta-analysis, Diabetologia, doi:10.1007/s00125-023-05928-1.
9.
Petrelli et al., Metformin and Covid-19: a systematic review of systematic reviews with meta-analysis, Acta Biomedica Atenei Parmensis, doi:10.23750/abm.v94iS3.14405.
10.
Oscanoa et al., Metformin therapy and severity and mortality of SARS-CoV-2 infection: a meta-analysis, Clinical Diabetology, doi:10.5603/DK.a2021.0035.
11.
Kan et al., Mortality Risk of Antidiabetic Agents for Type 2 Diabetes With COVID-19: A Systematic Review and Meta-Analysis, Frontiers in Endocrinology, doi:10.3389/fendo.2021.708494.
12.
Poly et al., Metformin Use Is Associated with Decreased Mortality in COVID-19 Patients with Diabetes: Evidence from Retrospective Studies and Biological Mechanism, Journal of Clinical Medicine, doi:10.3390/jcm10163507.
13.
Song et al., The Effect of Antihyperglycemic Medications on COVID-19: A Meta-analysis and Systematic Review from Observational Studies, Therapeutic Innovation & Regulatory Science, doi:10.1007/s43441-024-00633-6.
14.
Ganesh et al., Does metformin affect outcomes in COVID‐19 patients with new or pre‐existing diabetes mellitus? A systematic review and meta‐analysis, British Journal of Clinical Pharmacology, doi:10.1111/bcp.15258.
15.
Nassar et al., Noninsulin‐based antihyperglycemic medications in patients with diabetes and COVID‐19: A systematic review and meta‐analysis, Journal of Diabetes, doi:10.1111/1753-0407.13359.
16.
Zhan et al., Effect of Antidiabetic Therapy on Clinical Outcomes of COVID-19 Patients With Type 2 Diabetes: A Systematic Review and Meta-Analysis, Annals of Pharmacotherapy, doi:10.1177/10600280221133577.
17.
Nguyen et al., Preadmission use of antidiabetic medications and mortality among patients with COVID-19 having type 2 diabetes: A meta-analysis, Metabolism, doi:10.1016/j.metabol.2022.155196.
18.
Han et al., Association Between Anti-diabetic Agents and Clinical Outcomes of COVID-19 in Patients with Diabetes: A Systematic Review and Meta-Analysis, Archives of Medical Research, doi:10.1016/j.arcmed.2021.08.002.
19.
Chen et al., The Association Between Antidiabetic Agents and Clinical Outcomes of COVID-19 Patients With Diabetes: A Bayesian Network Meta-Analysis, Frontiers in Endocrinology, doi:10.3389/fendo.2022.895458.
20.
Scheen, A., Metformin and COVID-19: From cellular mechanisms to reduced mortality, Diabetes & Metabolism, doi:10.1016/j.diabet.2020.07.006.
Kow et al., 30 Sep 2020, peer-reviewed, 2 authors.
Newcastle-Ottawa Scale; OR, odds ratio. a The adjusted estimate was extracted in the analysis among patients with confirmed COVID-19 by polymerase chain reaction assay.
CONFLICT OF INTERESTS The authors declare that there are no conflict of interests.
Chia Siang Kow 1 Syed Shahzad Hasan
References
Bramante, Ingraham, Murray, Observational study of metformin and risk of mortality in patients hospitalized with Covid-19
Cariou, Hadjadj, Wargny, Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the COR-ONADO study, Diabetologia
Chen, Yang, Cheng, Clinical Characteristics and outcomes of patients with diabetes and COVID-19 in association with glucose-lowering medication, Diabetes Care
Crouse, Grimes, Li, Might, Ovalle et al., Metformin use is associated with reduced mortality in a diverse population with COVID-19 and diabetes
Davis, Xie, Viollet, Zou, Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase, Diabetes
Diabetes, Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2020, Diabetes Care43
El-Arabey, Abdalla, Metformin and COVID-19: a novel deal of an old drug
Esam, A proposed mechanism for the possible therapeutic potential of metformin in COVID-19, Diabetes Res Clin Pract
Hassan, Didari, Khan, Niaz, Mojtahedzadeh et al., A review on the protective effects of metformin in sepsis-induced organ failure, Cell J
Hattori, Suzuki, Hattori, Kasai, Metformin inhibits cytokineinduced nuclear factor kappaB activation via AMP-activated protein kinase activation in vascular endothelial cells, Hypertension
Koh, Kim, Kim, Ko, Kim, Anti-inflammatory mechanism of metformin and its effects in intestinal inflammation and colitis-associated colon cancer, J Gastroenterol Hepatol
Li, Huang, Zou, Epidemiology of COVID-19: a systematic review and meta-analysis of clinical characteristics, risk factors and outcomes
Liang, Ding, Li, Association of preadmission metformin use and mortality in patients with sepsis and diabetes mellitus: a systematic review and meta-analysis of cohort studies, Crit Care
Luo, Qiu, Liu, Metformin treatment was associated with decreased mortality in COVID-19 patients with diabetes in a retrospective analysis, Am J Trop Med Hyg
Moher, Liberati, Tetzlaff, Altman, Group, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, PLoS Med
Sharma, Ray, Sadasivam, Metformin in COVID-19: a possible role beyond diabetes, Diabetes Res Clin Pract
Singh, Singh, Is metformin ahead in the race as a repurposed host-directed therapy for patients with diabetes and COVID-19?, Diabetes Res Clin Pract
Ursini, Ciaffi, Landini, Meliconi, COVID-19 and diabetes: is metformin a friend or foe?, Diabetes Res Clin Pract
Wells, Shea, Connell, The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in metaanalyses
DOI record:
{
"DOI": "10.1002/jmv.26498",
"ISSN": [
"0146-6615",
"1096-9071"
],
"URL": "http://dx.doi.org/10.1002/jmv.26498",
"alternative-id": [
"10.1002/jmv.26498"
],
"archive": [
"Portico"
],
"assertion": [
{
"group": {
"label": "Publication History",
"name": "publication_history"
},
"label": "Received",
"name": "received",
"order": 0,
"value": "2020-08-13"
},
{
"group": {
"label": "Publication History",
"name": "publication_history"
},
"label": "Accepted",
"name": "accepted",
"order": 1,
"value": "2020-09-07"
},
{
"group": {
"label": "Publication History",
"name": "publication_history"
},
"label": "Published",
"name": "published",
"order": 2,
"value": "2020-09-30"
}
],
"author": [
{
"affiliation": [
{
"name": "School of Postgraduate Studies International Medical University Kuala Lumpur Malaysia"
}
],
"family": "Kow",
"given": "Chia Siang",
"sequence": "first"
},
{
"ORCID": "http://orcid.org/0000-0002-4058-2215",
"affiliation": [
{
"name": "Department of Pharmacy University of Huddersfield Huddersfield UK"
},
{
"name": "School of Biomedical Sciences & Pharmacy University of Newcastle Callaghan Australia"
}
],
"authenticated-orcid": false,
"family": "Hasan",
"given": "Syed Shahzad",
"sequence": "additional"
}
],
"container-title": [
"Journal of Medical Virology"
],
"content-domain": {
"crossmark-restriction": true,
"domain": [
"onlinelibrary.wiley.com"
]
},
"created": {
"date-parts": [
[
2020,
9,
11
]
],
"date-time": "2020-09-11T07:46:43Z",
"timestamp": 1599810403000
},
"deposited": {
"date-parts": [
[
2021,
5,
12
]
],
"date-time": "2021-05-12T15:52:02Z",
"timestamp": 1620834722000
},
"indexed": {
"date-parts": [
[
2022,
3,
28
]
],
"date-time": "2022-03-28T16:06:43Z",
"timestamp": 1648483603661
},
"is-referenced-by-count": 44,
"issn-type": [
{
"type": "print",
"value": "0146-6615"
},
{
"type": "electronic",
"value": "1096-9071"
}
],
"issue": "2",
"issued": {
"date-parts": [
[
2020,
9,
30
]
]
},
"journal-issue": {
"issue": "2",
"published-print": {
"date-parts": [
[
2021,
2
]
]
}
},
"language": "en",
"license": [
{
"URL": "http://onlinelibrary.wiley.com/termsAndConditions#vor",
"content-version": "vor",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2020,
9,
30
]
],
"date-time": "2020-09-30T00:00:00Z",
"timestamp": 1601424000000
}
},
{
"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1",
"content-version": "tdm",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2020,
9,
30
]
],
"date-time": "2020-09-30T00:00:00Z",
"timestamp": 1601424000000
}
}
],
"link": [
{
"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fjmv.26498",
"content-type": "application/pdf",
"content-version": "vor",
"intended-application": "text-mining"
},
{
"URL": "https://onlinelibrary.wiley.com/doi/pdf/10.1002/jmv.26498",
"content-type": "application/pdf",
"content-version": "vor",
"intended-application": "text-mining"
},
{
"URL": "https://onlinelibrary.wiley.com/doi/full-xml/10.1002/jmv.26498",
"content-type": "application/xml",
"content-version": "vor",
"intended-application": "text-mining"
},
{
"URL": "https://onlinelibrary.wiley.com/doi/pdf/10.1002/jmv.26498",
"content-type": "unspecified",
"content-version": "vor",
"intended-application": "similarity-checking"
}
],
"member": "311",
"original-title": [],
"page": "695-697",
"prefix": "10.1002",
"published": {
"date-parts": [
[
2020,
9,
30
]
]
},
"published-online": {
"date-parts": [
[
2020,
9,
30
]
]
},
"published-print": {
"date-parts": [
[
2021,
2
]
]
},
"publisher": "Wiley",
"reference": [
{
"article-title": "Epidemiology of COVID‐19: a systematic review and meta‐analysis of clinical characteristics, risk factors and outcomes [published online ahead of print August 13, 2020]",
"author": "Li J",
"journal-title": "J Med Virol",
"key": "e_1_2_2_2_1"
},
{
"DOI": "10.2337/dc20-S009",
"doi-asserted-by": "publisher",
"key": "e_1_2_2_3_1"
},
{
"article-title": "A review on the protective effects of metformin in sepsis‐induced organ failure",
"author": "Ismail Hassan F",
"first-page": "363",
"issue": "4",
"journal-title": "Cell J",
"key": "e_1_2_2_4_1",
"volume": "21",
"year": "2020"
},
{
"DOI": "10.1016/j.diabres.2020.108282",
"doi-asserted-by": "publisher",
"key": "e_1_2_2_5_1"
},
{
"DOI": "10.1016/j.diabres.2020.108183",
"doi-asserted-by": "publisher",
"key": "e_1_2_2_6_1"
},
{
"DOI": "10.1016/j.diabres.2020.108167",
"doi-asserted-by": "publisher",
"key": "e_1_2_2_7_1"
},
{
"DOI": "10.1016/j.diabres.2020.108268",
"doi-asserted-by": "publisher",
"key": "e_1_2_2_8_1"
},
{
"article-title": "Metformin and COVID‐19: a novel deal of an old drug [published online ahead of print April 29, 2020]",
"author": "El‐Arabey AA",
"journal-title": "J Med Virol",
"key": "e_1_2_2_9_1"
},
{
"article-title": "Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA statement",
"author": "Moher D",
"first-page": "264",
"issue": "4",
"journal-title": "PLoS Med",
"key": "e_1_2_2_10_1",
"volume": "151",
"year": "2009"
},
{
"key": "e_1_2_2_11_1",
"unstructured": "WellsG SheaB O'ConnellD et al. The Newcastle‐Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta‐analyses. 2013.http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. accessed Aug 8 2020"
},
{
"article-title": "Metformin use is associated with reduced mortality in a diverse population with COVID‐19 and diabetes",
"author": "Crouse A",
"journal-title": "medRxiv",
"key": "e_1_2_2_12_1",
"year": "2020"
},
{
"article-title": "Observational study of metformin and risk of mortality in patients hospitalized with Covid‐19",
"author": "Bramante CT",
"journal-title": "medRxiv",
"key": "e_1_2_2_13_1",
"year": "2020"
},
{
"DOI": "10.4269/ajtmh.20-0375",
"doi-asserted-by": "publisher",
"key": "e_1_2_2_14_1"
},
{
"DOI": "10.2337/dc20-0660",
"doi-asserted-by": "publisher",
"key": "e_1_2_2_15_1"
},
{
"DOI": "10.1007/s00125-020-05180-x",
"doi-asserted-by": "publisher",
"key": "e_1_2_2_16_1"
},
{
"DOI": "10.1186/s13054-019-2346-4",
"doi-asserted-by": "publisher",
"key": "e_1_2_2_17_1"
},
{
"DOI": "10.2337/diabetes.55.02.06.db05-1064",
"doi-asserted-by": "publisher",
"key": "e_1_2_2_18_1"
},
{
"DOI": "10.1161/01.HYP.0000221429.94591.72",
"doi-asserted-by": "publisher",
"key": "e_1_2_2_19_1"
},
{
"DOI": "10.1111/jgh.12435",
"doi-asserted-by": "publisher",
"key": "e_1_2_2_20_1"
}
],
"reference-count": 19,
"references-count": 19,
"relation": {},
"score": 1,
"short-container-title": [
"J Med Virol"
],
"short-title": [],
"source": "Crossref",
"subject": [
"Infectious Diseases",
"Virology"
],
"subtitle": [],
"title": [
"Mortality risk with preadmission metformin use in patients with COVID‐19 and diabetes: A meta‐analysis"
],
"type": "journal-article",
"update-policy": "http://dx.doi.org/10.1002/crossmark_policy",
"volume": "93"
}